Clinical trials
Metastatic Breast Cancer clinical trials
Below are recruiting metastatic breast cancer clinical trials, each written for real people, not researchers. We’re tracking 1,312 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07425002Recruiting
Precision Oncology Study in Breast Cancer (PRISM)
This study looks at tumor tissue from people with breast cancer, including those with brain metastases. It aims to learn more about the genetic changes in the cancer to help guide future treatments.
Dublin, LeinsterAges 18 years+ - NCT07424547RecruitingPhase 1
Study of SYS6043 for advanced or metastatic solid tumors
This trial tests a new study drug (SYS6043) for people with advanced or metastatic solid tumors that have not responded to or are not candidates for standard therapies. The drug targets a protein called B7-H3 on cancer cells to help stop tumor growth.
Plantation, FloridaAges 18 years+ - NCT04744506Recruiting
Targeted removal of armpit nodes after chemotherapy for breast cancer
This trial studies a more targeted surgery to remove cancer-involved lymph nodes in the armpit after you finish chemotherapy before surgery. It may help doctors better remove affected nodes while avoiding unnecessary tissue removal.
Hangzhou, ZhejiangAges 18–85 - NCT07413939RecruitingPhase 2/Phase 3
Study of RO7771950 vs tucatinib for HER2-positive breast cancer
This trial tests a new drug, RO7771950, against another drug called tucatinib. Both are given with standard chemotherapy to see which works better for advanced breast cancer that is HER2-positive. People with brain metastases may join.
Huntsville, AlabamaAges 18 years+ - NCT07409272RecruitingPhase 3
Study of setidegrasib with chemo for pancreatic cancer
This trial tests a new drug called setidegrasib, given with two types of chemotherapy (mFOLFIRINOX or NALIRIFOX), for people whose pancreatic cancer has spread and has a specific genetic change called KRAS G12D. The goal is to see if adding setidegrasib helps control the cancer better than chemo alone.
Tucson, ArizonaAges 18 years+ - NCT07410676RecruitingPhase 1/Phase 2
Donor NK cells with IL-15 and pembrolizumab for advanced solid tumors
This trial tests a new type of cell therapy (natural killer cells) made from a donor, combined with low-dose IL-15 (a protein that helps these cells work) and sometimes with pembrolizumab (Keytruda), for people with advanced solid tumors that have not responded to standard treatments. The goal is to see if this combination can shrink tumors or slow their growth.
Beijing, Beijing MunicipalityAges Any age - NCT07410494RecruitingPhase 1/Phase 2
Personalized donor cell therapy for advanced solid tumors
This trial tests a personalized cell therapy (CAR-NK) using donor immune cells that are engineered to find and attack one or two markers on advanced solid tumors. It may be an option for people whose tumors have these specific markers and have exhausted other treatments.
Beijing, Beijing MunicipalityAges 8–85 - NCT07405801RecruitingPhase 2
Inavolisib plus ribociclib plus fulvestrant for advanced breast cancer
This trial tests a combination of three drugs (inavolisib, ribociclib, and fulvestrant) compared to a placebo plus two of the drugs (ribociclib and fulvestrant) for people with advanced hormone receptor-positive breast cancer who have not had prior treatment for advanced disease. The goal is to see if adding inavolisib improves outcomes.
Anaheim, CaliforniaAges 18 years+ - NCT07401537RecruitingPhase 2
Comparing two schedules of immunotherapy for advanced triple-negative breast cancer
This trial tests whether giving immunotherapy less often (extended dose intervals) works as well as the standard schedule for people with advanced triple-negative breast cancer who have already completed 6 cycles of first-line treatment. It aims to see if a longer break between doses can be just as effective with fewer hospital visits.
Guangzhou, GuangdongAges 18–70 - NCT06642545RecruitingPhase 2
New targeted drug combo for HER2-low breast cancer
This trial tests a new combination of targeted drugs (Disitamab Vedotin and RC148) against a standard chemotherapy (Abraxane) with or without an immunotherapy drug (Toripalimab) for advanced breast cancer that is HER2-low and hormone receptor-negative. The goal is to see if the new combination works better at shrinking tumors and slowing cancer growth.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07389733RecruitingPhase 1/Phase 2
Study of HRS-6208 with other drugs for advanced breast cancer
This trial tests a new combination of drugs (HRS-6208 with HRS-8080, fulvestrant, or letrozole) for people with advanced or metastatic breast cancer that cannot be removed by surgery. It aims to see if these combinations can help shrink or slow the cancer.
Dalian, LiaoningAges 18–75 - NCT07390838RecruitingPhase 1
Study of SH009 for advanced solid tumors
This trial tests an investigational drug called SH009 for people with advanced solid tumors that have stopped responding to standard treatments. It aims to see if the drug is safe and effective.
ShanghaiAges 18 years+ - NCT07395336RecruitingPhase 2
Elacestrant and exemestane for HR+/HER2- breast cancer that has spread
This trial tests combining elacestrant (a new hormone therapy) with exemestane (a standard hormone therapy) for people whose HR+/HER2- breast cancer has spread and who have already tried a CDK4/6 inhibitor with anastrozole or letrozole. It may help if your tumor shows certain activity on a special PET scan.
Milan, ItalyAges 18 years+ - NCT07389967Recruiting
Nutrition awareness study for women after breast cancer treatment
This study looks at how aware women are about nutrition after finishing their main breast cancer treatment. It aims to help improve support for diet and healthy eating habits.
Chapel Hill, North CarolinaAges 18 years+ - NCT06259929RecruitingPhase 2
Neoadjuvant abemaciclib and giredestrant for early breast cancer
This trial tests a combination of two oral medications (abemaciclib and giredestrant) given before surgery to women with a common type of early breast cancer (hormone receptor-positive, HER2-negative). The goal is to see if this treatment can shrink the tumor before surgery.
Catania, CataniaAges 18 years+ - NCT04990921RecruitingPhase 2
Palliative radiation plus pembrolizumab for metastatic breast cancer
This trial studies whether adding a focused, comfort-focused form of radiation (SBRT) to pembrolizumab can help people with stage IV breast cancer that cannot be removed with surgery. You may be eligible if you can receive palliative SBRT and have measurable tumors, and if you meet prior-therapy and blood/health criteria.
Louisville, KentuckyAges 18 years+ - NCT07376174Recruiting
HER2-positive breast cancer and dual-target therapy study
This study looks at how well a combination of two targeted drugs (trastuzumab and pertuzumab) works for people with HER2-positive breast cancer that hasn't spread. It aims to understand how HER2 levels affect treatment outcomes after surgery.
Jinan, ShandongAges 18 years+ - NCT07371585RecruitingPhase 2
Trastuzumab Deruxtecan for first-line HER2-positive advanced breast cancer
This trial tests a targeted therapy called Trastuzumab Deruxtecan (T-DXd) for people with HER2-positive breast cancer that has spread or cannot be removed. It is for those who have not yet received any chemotherapy or HER2-targeted treatment for metastatic disease. The study also focuses on managing side effects early, using digital tools to track symptoms.
VillejuifAges 18 years+ - NCT07376538RecruitingPhase 2
Treating advanced breast cancer based on treatment response
This trial tests a personalized approach to treating breast cancer that has spread to nearby lymph nodes. Your surgery and radiation will be tailored to how well your cancer responds to initial chemotherapy or hormone therapy.
Beijing, Beijing MunicipalityAges 18–75 - NCT07377643RecruitingPhase 3
New drug combo for advanced HER2-positive breast cancer
This trial tests a new drug called IBI354 (an antibody-drug conjugate) given with or without pertuzumab, compared to the standard combination of taxane, trastuzumab, and pertuzumab, for people with HER2-positive breast cancer that has spread and who have not had prior treatment for advanced disease.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07368998RecruitingPhase 2
Study of inavolisib plus fulvestrant for advanced breast cancer
This trial tests whether a new targeted pill (inavolisib) plus hormone therapy (fulvestrant) can slow or stop breast cancer growth in people whose cancer has a specific genetic change called a PIK3CA mutation. It is for patients whose disease worsened after previous hormone-and-CDK-inhibitor treatment.
Los Angeles, CaliforniaAges 18 years+ - NCT07354022RecruitingPhase 3
Study of HRS-8080 with dalpiciclib for advanced breast cancer after hormone therapy fails
This trial tests a new combination of drugs (HRS-8080 and dalpiciclib) for women with advanced or metastatic breast cancer that has stopped responding to initial hormone therapy after surgery. It aims to see if this combination is safe and effective.
Beijing, Beijing MunicipalityAges 18–75 - NCT06851299RecruitingPhase 2
Trop2-ADC alone or with immunotherapy for advanced triple-negative breast cancer
This study tests a new drug called Trop2-ADC, either alone or combined with immunotherapy, for people with advanced triple-negative breast cancer. The goal is to see if it can shrink tumors and improve outcomes.
Guangzhou, GuangdongAges 18–70 - NCT06611891RecruitingPhase 3
PET scan study for breast cancer with hormone receptors
This study tests a special PET scan called 68Ga-DOTATOC to see if it can find certain breast cancer cells in the body. It may help doctors better understand your cancer, especially if it has spread to the liver or bones.
GrenobleAges 18–99
Hear when a new Metastatic Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for metastatic breast cancer?
- Yes. Clin2 currently lists 1,312 recruiting metastatic breast cancer studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a metastatic breast cancer trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a metastatic breast cancer trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Breast Cancer Early Stage Breast Cancer (Stage 1-3)
- Breast Cancer (Triple Negative Breast Cancer (TNBC))
- Locally Advanced or Metastatic Breast Cancer
- Metastatic Triple-negative Breast Cancer
- HER2-positive Metastatic Breast Cancer
- Advanced/Metastatic Breast Cancer
- Non-metastatic Breast Cancer
- Advanced or Metastatic Breast Cancer
Beyond the search
We also like to point to nonprofits doing real good in this area. We aren’t affiliated with them — we just admire the work.
- Stand Up To CancerPeople facing cancer across many types, through the research that leads to better treatments.
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.